Zybiraa 250mg Tablet (Abiraterone acetate)

Zybiraa 250mg Tablet is an anticancer medicine used in the treatment of prostate cancer. It is not for used in women & children. It contains Abiraterone Acetate (250mg) as an active ingredient that works by blocking an enzyme called CYP17 to inhibit the production of male hormone androgen (like testosterone). Results in control the progression of cancer. It can be used with certain other medicines as part of combination chemotherapy to enhance the effectiveness of treatment.

Prostate Cancer

The human body reacts differently to Zybiraa 250mg Tablet(Abiraterone acetate 250mg). Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention.

Some of the common side effects include:
● Fluid in legs or feet
● Low blood potassium
● High blood pressure
● Urinary tract infection
● Diarrhea
● High-fat levels in the blood
● Chest pain
● Irregular heartbeat
● Rapid heart rate
● Bone fracture
● Indigestion
● Blood in urine
● Rash
However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Take Zybiraa 250mg Tablet(Abiraterone acetate 250mg) in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition and stage of cancer. This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken on an empty stomach. Never skip a dose or double dose.

● Caffo, O., Veccia, A., Kinspergher, S., & Maines, F. (2018). Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. Future Oncology, 14(5), 431-442.
● Efstathiou, E., Titus, M., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A., ... & Logothetis, C. J. (2012). Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. Journal of clinical oncology, 30(6), 637-643.
● Attard, G., Murphy, L., Clarke, N. W., Cross, W., Jones, R. J., Parker, C. C., ... & Berthold, D. (2022). Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The lancet, 399(10323), 447-460.
● Ryan, C. J., & Cheng, M. L. (2013). Abiraterone acetate for the treatment of prostate cancer. Expert opinion on pharmacotherapy, 14(1), 91-96.
● Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018). Abiraterone acetate in the treatment of prostate cancer. Biomedicine & Pharmacotherapy, 101, 211-218.